论文部分内容阅读
目的:观察小剂量普伐他汀联合丹田降脂丸治疗混合型高血脂症的临床疗效及安全性。方法:混合型高血脂症患者192例,随机分为3组各64例,西药组采用小剂量普伐他汀治疗,中药组采用丹田降脂丸治疗,联合组采用小剂量普伐他汀联合丹田降脂丸治疗,治疗12周;12周时西药组、中药组血脂水平未全部达标者再随机分为3组,改联合组采用小剂量普伐他汀联合丹田降脂丸治疗,改西药组采用常规剂量普伐他汀治疗,改中药组采用丹田降脂丸治疗,再治疗12周。观察治疗前后血脂水平的变化及不良反应。结果:治疗12周后,3组血清总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)、甘油三酯(TG)水平均有不同程度的改善;3组治疗后比较,差异有显著性意义(P<0.05),联合组TC、LDL-C、TG 3项水平下降的幅度及HDL-C升高的幅度均大于西药组、中药组(P<0.05)。改联合组TC及LDL-C下降的幅度小于改西药组,但2组比较,差异无显著性意义(P>0.05),而改联合组TG下降的幅度及HDL-C升高幅度大于改西药组(P<0.01);改联合组TC、LDL-C降低的幅度大于改中药组(P<0.01),降低TG及升高LDL-C的幅度也大于改中药组(P<0.05)。结论:小剂量普伐他汀与丹田降脂丸联合用药治疗混合型高血脂症,较单独用药更有效,可全面改善血脂水平,具有良好的安全性和耐受性。
Objective: To observe the clinical efficacy and safety of low-dose pravastatin combined with Dantian Jiangzhi pill in the treatment of mixed hyperlipidemia. Methods: A total of 192 patients with mixed hyperlipidemia were randomly divided into three groups of 64 cases. The western medicine group was treated with low-dose pravastatin. The Chinese medicine group was treated with Dantian Jiangzhi pills. The combination group was treated with low-dose pravastatin combined with low-dose pravastatin 12 weeks, Western medicine group, traditional Chinese medicine group not all reached the standard of blood fat were randomly divided into three groups, the combination group using low-dose pravastatin combined with pubiclization lipid-lowering pills, the Western medicine group using conventional The dose of pravastatin treatment, the traditional Chinese medicine group treated with pubic liver lipid-lowering pills, and then treated for 12 weeks. Observe the changes of blood lipid level and adverse reactions before and after treatment. Results: After 12 weeks of treatment, the levels of total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C) and triglyceride (TG) (P <0.05). The decrease of TC, LDL-C, TG and the increase of HDL-C in the combined group were greater than those in western medicine group and traditional Chinese medicine group P <0.05). The decrease of TC and LDL-C in the combination group was smaller than that in the western medicine group, but there was no significant difference between the two groups (P> 0.05). However, the decrease of TG and the increase of HDL-C in the combination group were greater than that of the western medicine (P <0.01). The reduction of TC and LDL-C in the combination group was larger than that in the traditional Chinese medicine group (P <0.01), and the magnitude of lowering TG and LDL-C was also greater than that in the traditional Chinese medicine group (P <0.05). Conclusion: Low-dose pravastatin combined with low-fat Dan Tianjiang pills for the treatment of mixed hyperlipidemia, more effective than single drug, can fully improve blood lipid levels, with good safety and tolerability.